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Clinical drug dosing would, ideally, be informed by high-precision, patient-specific data
on drug metabolism. The direct determination of patient-specific drug pharmacokinetics
(“peaks and troughs”), however, currently relies on cumbersome, laboratory-based
approaches that require hours to days to return pharmacokinetic estimates based on only
one or two plasma drug measurements. In response clinicians often base dosing on age,
body mass, pharmacogenetic markers, or other indirect estimators of pharmacokinetics
despite the relatively low accuracy of these approaches. Here, in contrast, we explore
the use of indwelling electrochemical aptamer-based (E-AB) sensors as a means of
measuring pharmacokinetics rapidly and with high precision using a rat animal model.
Specifically, measuring the disposition kinetics of the drug tobramycin in Sprague-Dawley
rats we demonstrate the seconds resolved, real-time measurement of plasma drug levels
accompanied bymeasurement validation via HPLC-MS on ex vivo samples. The resultant
data illustrate the significant pharmacokinetic variability of this drug even when dosing
is adjusted using body weight or body surface area, two widely used pharmacokinetic
predictors for this important class of antibiotics, highlighting the need for improved
methods of determining its pharmacokinetics.
Keywords: aptamer-based sensors, therapeutic drug monitoring, pharmacokinetics, aminoglycosides, body
surface area
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INTRODUCTION
A drug’s pharmacokinetics can vary widely from patient to
patient (Kiang et al., 2014; Reichel and Lienau, 2016) due to, for
example, genetic differences (Hayashi, 2013). Indeed, clinically
significant variability is even seen day-to-day within a single
individual (DeGorter et al., 2012; Schell et al., 2014) due to, for
example, drug interactions (Zhang et al., 2009), diet (Bressler,
2006; El-Demerdash et al., 2012; Toh et al., 2014), physical
activity (Sidhu et al., 2011; Janukonyte et al., 2014; Zourikian
et al., 2016) or health status (Roberts and Lipman, 2009; Roberts
et al., 2014; Sinnollareddy et al., 2015). To combat this variability
clinicians are increasingly turning to personalized medicine,
which seeks to tailor treatment to the individual, taking into
consideration each patient’s unique response to therapy, with the
goal being to maximize efficacy, and minimize adverse reactions
(Aspinall and Hamermesh, 2007).
Ideally, personalized medicine would be informed by high-
precision, patient-specific data regarding drug pharmacokinetics.
The accuracy with which current methods (“peaks and troughs”)
are able to define this, however, is poor as the approach
relies on only one or two measurements of plasma drug levels
(Gross, 1998). Moreover, as the approach requires blood draws
and laboratory measurements it is also slow and cumbersome,
returning an answer only hours to days after sample collection
(Gross, 1998). Because of these limitations dose determination
is thus instead often performed using indirect predictors of
pharmacokinetics (Poulin et al., 2011). Among these are the
century-old body surface area (BSA)-based calculations, the first
of which was derived from the data of only 9 patients (Shuter
and Aslani, 2000) and went unconfirmed for 60 years (Haycock
et al., 1978). Even today, BSA-based dose determination remains
common, beginning in Phase I preclinical trials (FDA), where
the BSA-pharmacokinetic relationships of animals are based
on body mass and scaled non-linearly to infer the appropriate
BSA-based dosing for humans (Reagan-Shaw et al., 2008; Nair
and Jacob, 2016).
Despite its continued, widespread use, BSA-based dose
determination suffers from potentially serious limitations. First,
it is poorly correlated with the pharmacokinetics of many
classes of drugs (Gurney, 1996; Dooley and Poole, 2000; Felici
et al., 2002), often leading to suboptimal dosing (Sawyer and
Ratain, 2001; Baker et al., 2002; Gao et al., 2008), including
both inefficacious underdosing, and potentially lethal overdosing
(Grochow et al., 1990). Second, BSA calculations fail to account
for abnormal body sizes (Gurney and Shaw, 2007; Pai, 2012) or
genetic variation across populations (Gurney, 1996, 2002). The
field of pharmacogenetics seeks to overcome that latter factor by
tailoring dosing to the specific genetic background of individual
patients, but to date this is still poorly understood, lacks
consistency in clinical outcomes, and has failed to adequately
predict individual drug response (Shah and Shah, 2012). Simply
put, current approaches to dose-determination fall far short of
the demands of truly personalized, high-precision medicine.
In response to the pressing need for improved methods of
defining patient-specific pharmacokinetics we have developed
a platform that can measure drug concentrations in situ
in the body conveniently and with high frequency, thus
enabling unprecedented precision in the determination of
pharmacokinetics (Arroyo-Curras et al., 2017b). Our approach
employs electrochemical aptamer-based (E-AB) sensors, a
platform comprised of a redox-reporter-modified, target-binding
aptamer (a nucleic acid selected for its ability to bind the
target of interest) that is covalently attached to an interrogating
electrode (Figure 1A). This, in turn, undergoes a binding-
induced conformational change that alters the approach of
the reporter to the electrode surface, producing an easily
measurable change in current upon interrogation via square
wave voltammetry (Figure 1B). This conformation-change-
linked signal transduction mimics the mechanisms employed by
naturally occurring receptors in the body (Ricci et al., 2016),
rendering the E-AB platform unique among general sensing
architectures in its ability to operate in situ in the living
body (Figure 1C) (Arroyo-Curras et al., 2017a,b). Here, we
validate this technology in a rat animal model by comparison
to gold-standard ex-vivo (HPLC-MS) measurements before
demonstrating its unparalleled precision in the determination of
drug pharmacokinetics.
METHOD
We selected the disposition kinetics of the antibiotic tobramycin
as our test bed. This drug is generally dosed following averaged
pharmacokinetic data collected from a large population (Inciardi
and Batra, 1993) which establishes plasma concentrations
below 6µg/mL (11µM) as potentially ineffective [depending
on the pathogen’s minimum inhibitory concentration (Roberts
et al., 2008; Cobussen et al., 2015; Baclet et al., 2017)] and
above 50µg/mL (88µM) as frequently nephrotoxic or ototoxic
(Whelton et al., 1976; Moore et al., 1984; Wood et al.,
1988; McCormack and Jewesson, 1992; Eliopoulos, 2007; Lee
et al., 2017). When coupled with significant patient-to-patient
metabolic variability (Avent et al., 2011) the narrowness of this
therapeutic window renders tobramycin’s dosing a significant
clinical challenge (de Velde et al., 2018).
To calibrate our approach against the “gold-standard”
analytical method we performed tobramycin E-AB
measurements, and blood sampling for HPLC-MS analysis
in two independent groups of rats (see Materials and Methods).
We did this, as opposed to simultaneously performing E-AB
measurements and blood sampling in the same rat, to avoid
surgically blocking two major veins of the animals in any single
experiment, which would affect the drug’s pharmacokinetic
profile. Specifically, for the E-AB measurements we emplaced
sensors in the right jugular vein of rats and continuously (every
7 s) measured tobramycin levels following IM administration
of the drug (20 mg/kg) to the thigh. Our E-AB sensors can
measure in-vivo plasma tobramycin levels in the range of few
(exact limit of detection is 5µM) to hundreds of micromolar.
A full description of the procedure for the surgical placement
of E-AB sensors is given in the Materials and Methods section.
For HPLC-MS sampling, we collected blood samples (at 0,
1, 5, 10, 30, and 60min, 1min collection time) from the left
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FIGURE 1 | Electrochemical, aptamer-based (E-AB) sensors support the real-time measurement of drug concentrations in situ in the body. (A) E-AB sensors consist
of a redox-reporter-modified aptamer (a nucleic acid selected for its ability to bind the target of interest) tethered to an interrogating electrode. In the presence of the
target molecule a binding-induced conformational change alters the rate of electron transfer from the reporter, (B) altering the peak currents observed when the
sensor is interrogated using square wave voltammetry at 30 and 200Hz. This electrochemical method is highly sensitive to small changes in electron transfer thus
making it ideal for the interrogation of E-AB sensors. (C) With a diameter of just 225µm, the E-AB sensors we employed are narrow enough to emplace inside the
jugular vein of live rats, supporting in-vivo measurements. The comparison of (D) E-AB vs. (E) gold standard HPLC-MS pharmacokinetics measured on two
independent animals following intramuscular dosing of tobramycin (20 mg/kg) shows that the differences between the two profiles fall well within the range of
animal-to-animal variability (see below). (F) To highlight animal-to-animal variability we present here pharmacokinetic data collected on 12 individual female and male
rats, with weights spanning 350–500g, illustrating the precision with which the few-second time resolution of E-AB sensors enables the high-precision tracking of the
tobramycin’s adsorption, distribution, and excretion kinetics.
jugular vein of rats, which we then processed to isolate plasma,
and stored in ice. Briefly, for the ex-vivo analysis of samples
via HPLC-MS we first diluted the isolated plasma by 50% in
acetonitrile and centrifuged the samples to precipitate out any
protein components. We then removed the acetonitrile from the
supernatant with dichloromethane, which, after centrifuging,
induced a phase partition leaving the tobramycin-containing
water at the top, which we subsequently analyzed via HPLC-MS.
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We calibrated this approach using tobramycin standards and
accounted for dilution andmatrix effects via standard spiking; we
provide a full description in the Materials and Methods section.
RESULTS
E-AB sensors produced plasma levels and pharmacokinetic
parameters closely comparable to those obtained via HPLC-MS
measurements (Figures 1D,E). But because E-AB measurements
are far more frequent, they produce much more precise
pharmacokinetic parameter estimates. Specifically, while the
cumbersome nature of blood draws and the limited amount of
blood we can remove from a rat without causing undue harm
limited our ex-vivo measurements to just 7 time points, the 7 s
measurement frequency of E-AB measurements leads to many
hundreds of data points collected per pharmacokinetic profile
(Figures 1D,E). Performing least-squares regression analysis of
both the E-AB and HPLC-MS data against a one compartment,
open pharmacokinetic model with first order drug absorption
and elimination kinetics (Loftsson, 2015) we find that this
typically translates into a ∼3-fold improvement in the precision
with which we measured the uptake phase of the drug, γ, and
a ∼5-fold improvement in the determination of the elimination
phase, ß. Of note, it appears likely that the precision of the later
estimate is limited not by the number of data points we collect but
instead by the fact that, at this level of precision, ß is no longer a
constant as it fluctuates depending on hour-to-hour variations in
the animal’s kidney function (Arroyo-Currás et al., 2018).
The unprecedented precision of E-AB-derived
pharmacokinetic measurements provides an opportunity
for new insights into pharmacokinetic variability. To see
this, we employed E-AB sensors to record tobramycin
pharmacokinetic profiles in a total of 22 Sprague-Dawley rats (12
representative measurements are shown in Figure 1F) following
IM administration. To determine the relative variability between
subjects, we performed least-squares fit of the data against
the one compartment model and performed Monte Carlo
propagation of the errors from these fits to determine the 95%
confidence interval on each parameter (Table S1). E-AB sensors
revealed up to 4-fold differences in the areas under the curve
(AUC) recorded between subjects; for example, female rat 1 (19
± 1µM h) vs. rat 5 (74 ± 2µM h), and male rat 11 (24 ± 3µM
h) vs. rat 22 (104± 3µM h) in Table S1.
In addition to studying tobramycin pharmacokinetics
following IM injections, we also explored IV injections,
which are the standard of care for patients receiving
aminoglycoside therapy (Loewenthal and Dobson, 2010).
We did so (over 1-min injection duration) in a total of 17 rats (12
representative measurements are shown in Figure 2A). Given the
unprecedented time resolution of E-AB sensors we easily resolve
two exponential phases in most of the profiles, corresponding
to α, the distribution of the drug and ß, its elimination. Here,
again, we calculated pharmacokinetic variability by performing
a least-squares fit of each profile, except this time we employed
a two compartment open pharmacokinetic model of a bolus
injection (Loftsson, 2015). The pharmacokinetic parameters
resulting from this analysis (Table S2) demonstrate that
although both the distribution and elimination of tobramycin
vary significantly between subjects, the major source of
variability originates from ß (∼6-fold), which is reflected in
the area under the drug profiles and thus the absolute dose
delivered. Since drug elimination depends strongly on the overall
metabolic rate of each subject at the time of measurement, this
parameter has a strong influence in the bioavailability of the
drug. This observation agrees with a previous report where
we demonstrated time-dependent fluctuations in ß within
individual animal subjects following serial intravenous injections
of tobramycin (Arroyo-Curras et al., 2017b).
The high-precision measurements provided by E-AB sensors
highlight the poor precision of existing predictors of tobramycin
pharmacokinetics. Specifically, none of the pharmacokinetic
parameters extracted from profiles derived from intravenous
drug infusions (Figures 2B–E) exhibit any significant correlation
to BSA or other body parameter we explored, including weight
or sex, the state-of-the-art metrics used in the clinic to determine
the dosage of many drugs. As an example, least-squares analysis
of the areas under the drug profiles produce a linear correlation
coefficient of R2 = 0.096 (Figure 2E) indicating no significant
relation between drug exposure and BSA.
DISCUSSION
Here we have explored the use of E-AB sensors as a means
of easily and rapidly obtaining the pharmacokinetic profiles of
individuals with unprecedented precision, using the disposition
kinetics of tobramycin in Sprague-Dawley rats as our model
system. Comparison with ex-vivo measurements performed
using gold-standard HPLC-MS highlights both the accuracy
of E-AB sensors and the pharmacokinetic precision provided
by their far greater temporal resolution. The vastly improved
precision of this approach renders it easy to identify significant
subject-to-subject variability in drug levels following BSA-
adjusted dosing, an approach long considered the gold standard
for dosing tobramycin. For example, at the extremes of our
animal population receiving intravenous infusions, we observed
>50% variance in all pharmacokinetic parameters and no linear
correlation between these parameters and BSA (Figures 2B–E)
or any of a number of other potential predictors, including
weight, and sex. These results confirm the empirically known
inaccuracy of BSA, or body-based approaches in general, as
metrics for dose determination in this class of drugs (Horrevorts
et al., 1985; Touw et al., 1994; Hennig et al., 2008), and, more
broadly, emphasize the need for technologies supporting real-
time therapeutic drug monitoring of drugs to achieve effective
patient-specific, metabolism-responsive drug dosing.
BSA calculations were developed a century ago based on data
from healthy adults of average physique which, as demonstrated
both by our real-time measurements and empirically by
clinicians, are woefully inaccurate (Redlarski et al., 2016). This
is particularly true for the most grievously ill patients, who
are the very patients for which the margin for clinical error is
smallest (Felici et al., 2002). Specifically, clinical studies of the
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FIGURE 2 | Ultra-high-precision E-AB pharmacokinetic measurements following intravenous administration (20 mg/kg) of tobramycin (A) reveal important
inter-subject variability in the (B) distribution and (C) elimination phases, as well as the (D) maximum plasma concentration and the (E) area-under-the-curve in male,
and female Sprague-Dawley rats. Error bars indicate the standard error determined by performing a least-squares fit of the drug profiles to a two-compartment
pharmacokinetic model.
aminoglycosides have reported the need of specialized dosing
regimens for obese patients (Bauer et al., 1983). This, in turn,
has pushed clinicians to develop modified formulas for specific
populations, for example, patients varying by body composition
[e.g., obese (Pai, 2012) vs. lean body mass (Lim et al., 2006)]
and age [e.g., the elderly (Bevc et al., 2011) vs. children (Vaudry
et al., 2009)]. Recent studies have likewise found that BSA-based
dosing does not accurately capture drug pharmacokinetics in
demographically distinct groups [e.g., Korean (Cho et al., 2010),
Japanese (Kouno et al., 2003), and Arab (Al-Khader et al., 2008)
patients vs. Caucasian]. Despite the overwhelming evidence that
BSA is an inaccurate method for dose determination, however,
the U.S. Food and Drug Administration nevertheless continues
to recommend BSA-based dose scaling from preclinical studies
to human trials (Blanchard and Smoliga, 2015), an approach
that many scientists and clinicians discourage (Price and Frazier,
1998). Given the documented variability in patient-specific drug
pharmacokinetics and inaccuracy of using BSA-based dosing,
our platform helps resolve these issues by providing real-time,
individualized drug pharmacokinetics.
More broadly, the ability to measure in vivo drug
concentrations with seconds resolution offers unprecedented
opportunities for pharmacological research and clinical drug
therapy. In research, this ability could allow us to study drug
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pharmacokinetics of large cohorts while strictly controlling
disposition variability. In addition, real-time, in-vivo drug
measurements could also help in the scaling of drug dosages
from non-clinical animal studies to clinical human trials,
aiming to eliminate the use of ineffective or toxic drug levels
during drug development. In the clinic, this platform could
be employed for feedback-controlled drug delivery, in which
the measured levels of drugs, and disease biomarkers could be
used as inputs to achieve health-responsive and personalized
dosing drug therapy (Kim and Dionne, 2009; Liu et al.,
2014). Thus, the E-AB measurements we presented here
illustrate some of these possibilities and will hopefully inspire
the development of other platforms supporting continuous,
in-vivo sensing.
MATERIALS AND METHODS
Chemicals and Materials
Sodium hydroxide, sulfuric acid, tris (hydroxymethyl)
aminomethane (Tris), ethylenediaminetetraacetic acid (EDTA),
sodium hydrogen phosphate, sodium chloride, potassium
chloride, and potassium dihydrogen phosphate were ordered
from Fisher Scientific (Waltham, MA). 6-Mercapto-1-hexanol
and tris(2-carboxyethyl)phosphine were ordered from Sigma
Aldrich (St. Louis, MO). USP grade tobramycin sulfate was
purchased from Gold BioTechnology (St. Louis, MO). A 1X
stock solution of phosphate buffered saline (PBS) was prepared
by mixing 8 g of sodium chloride, 0.2 g of potassium chloride,
1.44 g of sodium hydrogen phosphate, and 0.24 g of potassium
hydrogen phosphate in 800mL of distilled water. The pH of this
solution was adjusted to 7.4 using hydrochloric acid and the
volume was adjusted to 1 L. A 1X stock solution of Tris-EDTA
buffer was prepared by mixing 1ml of 1M Tris-HCl (pH 8.0)
with 0.2ml EDTA (0.5M), adjusting the final volume to 100mL.
All chemicals were used as received.
The E-AB sensors employed here were adapted from previous
work (Wang and Rando, 1995; Rowe et al., 2010; Ferguson
et al., 2013; Arroyo-Curras et al., 2017b). To fabricate them
we ordered methylene-blue-and-thiol-modified DNA constructs
from Biosearch Technologies (Novato, CA) with the sequence:
5′ − HS− (CH2)6 − GGGACTTGGTTTAGGTAATGAG
TCCC− (CH2)7 −NH−MethyleneBlue− 3
′.
The 5′ end was modified with a hexanethiol linker and the
3′ end with a carboxy-modified methylene blue attached to the
DNA via the formation of an amide bond to a primary amine
on a 7-carbon linker. The structure of the exact methylene blue
modification is available at the manufacturer’s website (Biosearch
Technologies, Inc.). The modified DNAs were HPLC purified by
the supplier and used as received. Upon receipt each construct
was dissolved to 200µM in 1X Tris-EDTA buffer and frozen at
−20◦C in individual aliquots until use.
Catheters (22G) and 1mL syringes were purchased from
Becton Dickinson (Franklin Lakes, NJ). Gold and silver wires
(25µm diameter) were purchased from A-M systems (Sequim,
WA). To employ the silver wires as reference electrodes they
were immersed in bleach overnight to form a silver chloride
film. Heat-shrink polytetrafluoroethylene insulation (PTFE, HS
Sub-Lite-Wall, 0.02, 0.005, 0.003 ± 0.001 in, black-opaque, Lot #
17747112-3) to use on the gold and silver wires was purchased
from ZEUS (Branchburg Township, CA).
E-AB Sensor Fabrication
Segments of gold and silver wire 20 cm in length were cut to
make sensors. These wires were then insulated, first individually
and then together, by applying heat to shrinkable tubing around
the body of the wires. The sensor window (i.e., the region
without insulation) was approximately 3mm in length for the
gold wire and 6mm for the silver wire. The edge opposite to the
sensor window was left without insulation for a length of 1 cm
for both wires. To increase surface area (Arroyo-Curras et al.,
2017a) of the as prepared gold electrodes (to obtain larger peak
currents) the sensor surface was roughened electrochemically via
immersion in 0.5M sulfuric acid followed by potential jumping
between Einitial = 0.0V to Ehigh = 2.0V vs. Ag/AgCl, back and
forth, for 100,000 pulses. Each pulse was of 2ms duration with
no “quiet time.”
To fabricate sensors an aliquot of the DNA construct was
thawed and then reduced for 1 h at room temperature with
a 1,000-fold molar excess of tris(2-carboxyethyl)phosphine. A
freshly roughened gold electrode was then rinsed in di-ionized
water before being immersed in DNA at 200 nM in PBS for 1 h
at room temperature. Following this the sensors were immersed
overnight at 4◦C for 12 h in 20mM 6-mercapto-1-hexanol in PBS
to coat the remaining gold surface and remove non-specifically
adsorbed DNA. After this the sensors were rinsed with deionized
water and stored in PBS.
Electrochemical Methods and Data
Processing
To determine in-vivo drug levels E-AB sensors were interrogated
using square wave voltammetry from 0.0V to −0.5V vs.
Ag/AgCl, using an amplitude of 50mV, potential step sizes of
1–5mV, and varying frequencies from 10 to 500Hz. The files
corresponding to each voltammogram were recorded in serial
order using macros in CH Instruments software. The post-
experiment analysis of results was carried out using a script coded
in Igor Pro 7.
HPLC-MS Validation
The LC-MS/MS analysis was performed on an Agilent 1,290
HPLC coupled with an Agilent 6,470 Triple Quad detector.
The column used was an Agilent ZORBAX HILIC Plus 2.1 ×
100mm, 1.8-Micron (p/n: 959758-901). Optimum retention of
tobramycin was achieved using an isocratic mobile phase of 90%
20mM ammonium formate, 0.1% formic acid in water (mobile
phase A), 10% Acetonitrile (mobile phase B). The flow rate was
0.2 ml/min and injection volume was 10 ul. The column oven
temperature was set to 30◦C. Mass spectral setting was in positive
ionization mode, with gas temperature at 330◦C, gas flow at
13.0 L/min, nebulizer gas at 40 PSI, sheath gas temperature at
395◦C, sheath gas flow at 12 L/min, capillary voltage at 2,000V
and nozzle voltage at 0V. Quantification was performed using
multiple reaction monitoring (MRM) of the transitions of m/z
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468.3 to m/z 163.1 as quantifier, and m/z 468.3 to m/z 324.1
as qualifier.
Standard stock solutions of tobramycin were prepared in
water at a concentration of 1 mg/ml (∼1.7mM). These were
diluted to 100 ug/ml (∼175µM) with methanol: water (1:1) as
working solution. All solutions were stored in amber bottles and
kept in 4◦C storage room until use. Matrix matching calibration
standards at concentrations of 2,500, 7,500, 15,000, 25,000,
35,000, 50,000 ng/mL were prepared using blank rat serum
extract. The limit of detection (LOD) and limit of quantitation
(LOQ) were determined by diluting tobramycin standards till
concentrations with signal-to-noise close to 3 (LOD) or 10
(LOQ). In this study, LOD for tobramycin is 1 ng/ml and LOQ
is 3.3 ng/ml.
To prepare samples for HPLC-MS analysis, 500 uL of rat
serum were mixed and vortexed with 500 uL of acetonitrile
(ACN) for 3min, followed by centrifugation at 14.8 × 103
RPMs for 10min to precipitate out serum proteins. Then 1ml
of supernatant was transferred into a new vial and mixed
with 500 uL of dichloromethane (DCM), vortexed for 3min,
followed by centrifugation at 14.8 × 103 for 10min. In this step,
DCM was miscible with ACN and partitioned away from water.
Tobramycin stayed in the water phase (the upper layer). 400
uL of this supernatant was mixed and vortexed with 400 uL of
deionized water, then recentrifuged at 14.8 × 103 for 10min to
partition out any DCM left. Finally, 600 uL of supernatant was
filtered through a 0.22 um Whatman filter and transferred into
vials for HPLC-MS analysis.
In-vivo E-AB Measurements
All in vivo measurements were performed using a two-electrode
setup in which the reference and counter electrodes were a
silver wire coated with a silver chloride film as described above.
The measurements carried out in vivo were recorded using a
handheld potentiostat (Model 1242 B) from CH Instruments
(Austin, TX). A 30min sensor baseline was established before
the first drug infusion. For IV injections, a 3mL syringe filled
with tobramycin solution was connected to the sensor-free
catheter (placed in the jugular opposite that in which the sensor
was emplaced) and to a motorized syringe pump (KDS 200,
KD Scientific Inc., Holliston, MA). After establishing a stable
baseline, the drug was infused through this catheter at a rate
of 0.25 mL/min, using a stock solution of tobramycin (0.1M
solution; homemade). During and after drug infusion, recordings
were taken every 7 s for up to 3 h. The real-time plotting and
analysis of voltammetric data were carried out with the help of
custom MATLAB scripts.
Regression Analysis Using Monte Carlo
Propagation
We performed non-linear regression analysis of our
concentration/time data using two pharmacokinetic models:
(1) a two-compartment open model for intravenous injections
and (2) a one-compartment open model with first-order drug
absorption for intramuscular injections (Loftsson, 2015). The
equations employed in the regressions were the following:
For IV injections:
CP=Ae
− t
α+Be
− t
β (1)
For IM injections:
CP=
CMAX
γ
(
1
γ
− 1
β
)
[
e
− t
β−e
− t
γ
]
(2)
We carried out our data analysis using in-house-coded Matlab R©
scripts. Our analysis consisted of mathematically fitting the
pharmacokinetic profile corresponding to each drug injection
to either Equation 1 or Equation 2, depending on the route of
administration. During the regression analysis, the best fit of the
corresponding model to the experimental data was determined
by minimizing the least-square errors via Nelder-Mead simplex
algorithm (Lagarias et al., 1998), in which the parameters were
allowed to float unconstrained to obtain the values of: the
maximum drug concentration, CMAX, and the drug’s lifetimes for
the distribution, α, elimination, β , and uptake, γ, phases. We
note that α specifically refers to distribution of the drug from
the bloodstream into tissues following an IV injection and γ is
the uptake phase following an IM injection, i.e., the diffusion
of the drug from muscle tissue and into the bloodstream. We
performed Monte Carlo iterations to provide the variability
distribution of the calculated parameters and the area under the
curve. Specifically, in each Monte Carlo iteration we propagated
the root-mean-square error into our experimental data and
fit the resulting dataset to the model to extract a new set of
pharmacokinetic parameters. We repeated this process for 5,000
times (a number of iterations large enough to ensure convergence
of the simulation) for each injection dataset and then used the
newly generated pool of parameters to report the uncertainty on
the pharmacokinetic parameters as the 95% confidence interval
derived from the distribution of parameters.
Animals
Healthy adult (mean age= 9 weeks) male (mean weight= 300 g)
and female (mean weight = 200 g) Sprague-Dawley rats were
ordered from Charles River (Hollister, CA) and same-sex pair-
housed with autoclaved wood chip bedding in a 12 h light/dark
cycle (all procedures were conducted during the middle half of
the light phase of the light/dark cycle), temperature (mean =
25◦ C), and humidity (mean = 71%) controlled vivarium with
ad libitum access to food and water. All animals were allowed
a minimum of 48 h to habituate to the vivarium prior to the
experiment and assessed for welfare prior to use. All animals
were naïve to the drug and test procedures. Selection of our
animal cohorts initially started with a group of male rats (n =
8) for intramuscular (IM) and, upon noting substantial inter-
subject variability, we were motivated to repeat the IM injections
in males and add females to investigate potential variability in
pharmacokinetics following IV injections between the two sexes.
This led to a discrepancy in the number of animals in each sex
for the intramuscular injection condition. Except for the initial
group of males, rats of each sex were randomly allocated to either
the IM or IV group. A total of 40 animals were used for all
Frontiers in Molecular Biosciences | www.frontiersin.org 7 August 2019 | Volume 6 | Article 69
Vieira et al. High-Precision Drug Monitoring for Personalized Medicine
procedures, 22 for IM procedures (15 male and 7 female) and 18
for IV procedures (8 male and 10 female). All of the experimental
procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of California Santa
Barbara and adhered to the guidelines given by the NIH Guide
for Care and Use of Laboratory Animals (2011).
Study Design
Single animals serve as the experimental units for this study and
analyses were done on an individual basis. Overall, 4 separate
groups of animals were analyzed: male and female rats injected
either with intramuscular (male n = 15, female n = 7) or
intravenous (male n= 8, female n= 10) drug. Following surgical
preparation, baseline recordings were initially taken to serve
as a control comparison for post-injection recordings. Analyses
primarily focused on comparing subject-to-subject differences in
drug pharmacokinetics.
Surgical Procedures
For in vivomeasurements rats were induced under 5% isoflurane
anesthesia in a Plexiglas anesthesia chamber and thenmaintained
on 2–3% isoflurane gas via a nosecone for the duration of the
experiment. While anesthetized, E-AB sensors were inserted into
the right jugular vein and for rats receiving IV tobramycin,
an infusion line was inserted into the opposite, left, jugular
vein. Briefly, the area above each jugular vein was shaved
and cleaned with betadine, and 70% ethanol. A small incision
was made above each vein, and then each vein was isolated.
A small hole was cut into each vein with spring-loaded
microscissors. Into one, we inserted the E-AB sensor and in
the other, we inserted a silastic catheter constructed with a
bent steel cannula with a screw-type connector (Plastics One,
Roanoke, VA) and silastic tubing (11 cm, i.d., 0.64mm, o.d.,
1.19mm, Dow Corning, Midland, MI) for infusions. Both the
E-AB sensor and the infusion line were tied into place with
sterile 6–0 silk suture (Fine Science Tools, Foster City, CA),
then 30 units of heparin was infused into the vein prior to
establishing baseline recordings, and response to drug challenge
(see above). Following experimental procedures, all animals were
immediately euthanized.
A separate group of rats (n = 2) were used for ex vivo
measurements of tobramycin. Rats were anesthetized as above
and an infusion line was emplaced in the left jugular and a
collection line (same as infusion line) was emplaced in the right
jugular. Then, rats received an IM injection of tobramycin (20
mg/kg) and blood was periodically collected by applying negative
pressure to a syringe attached to the infusion line. Blood was
centrifuged at 2,500 RPM to separate serum, serum was extracted
with a micropipette, and then stored for subsequent analyses
by HPLC-MS.
Experimental Outcomes
The primary goal of these experiments was to study subject-to-
subject variability in pharmacokinetic measurements. This was
assessed by comparing E-ABmeasurements of in-vivo drug levels
across animals of differing sex and BSA following either IM or IV
infusion of the target compound (tobramycin).
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